What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey


METİNTAŞ S., AK G., DÜNDAR E., METİNTAŞ M.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.27, sa.7, ss.1202-1211, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 7
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s10147-022-02168-y
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1202-1211
  • Anahtar Kelimeler: Malignant mesothelioma, Join point regression analysis, Histopathological diagnosis, Chemotherapy, Multimodality treatment, WORLD-HEALTH-ORGANIZATION, EXTRAPLEURAL PNEUMONECTOMY, PLEURAL MESOTHELIOMA, TREATMENT PATTERNS, CLASSIFICATION, ASBESTOS, CISPLATIN, DIAGNOSIS, EXPOSURE, OUTCOMES
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objectives To investigate the changes in epidemiological and survival characteristics of malignant mesothelioma (MM) cases diagnosed in a 30-year period between 1990 and 2019. Methods Data were analyzed considering three time periods (1990-1999, 2000-2009, 2010-2019) when treatment practices changed. The Join point Regression Program was used to analyze the change in clinical and epidemiological characteristics of the cases. Kaplan-Meier analysis was used to calculate the overall survival of the patients. Cox regression analysis was used to determine the effect of variables on survival. Results The study group consisted of 928 MM patients. During the study period, the mean age of the patients and the percentage of epithelioid subtype increased, while the percentage of female and histopathologically unidentified cases decreased. The median survival (95%CI) of patients according to the study periods was 9.0 (7.2-10.9), 9.0 (7.6-10.4) and 12.0 (10.5-13.5) months, respectively. A significant increase in overall survival was observed in the time trend (p = 0.013). There was no significant change in overall survival in patients receiving best supportive care over the 30-year period (p = 0.060), but an improvement of 1.4 (95%CI 0.2 to 2.7) months (p = 0.027) was observed in patient receiving chemotherapy. An improvement in overall survival of 4.8 (1.2 to 8.4) months was also observed in patients receiving multimodality treatment during 2000-2019 (p = 0.014). MM patients who were younger, female, diagnosed after 2000, epithelioid subtype, early stage, and received chemotherapy or multimodal treatment had longer survival. Conclusions It was found that histopathological diagnosis and treatment success in MM have improved over the years.